Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial
Authors' conclusion
Petrelintide achieved clinically meaningful weight reduction and had similar gastrointestinal tolerability to that of placebo apart from predominantly mild nausea during dose escalation
Study context
- Population
- Adults ≥18 years without T2D, BMI ≥30 kg/m² or ≥27 kg/m² with hypertension and/or dyslipidaemia; 32 sites in Poland, Romania and the USA485 received ≥1 dose
- Participants
- 493 adults
- Comparison
- Once-weekly petrelintide vs placebo
- Petrelintide 1.0 mgn = 79
- Petrelintide 2.5 mgn = 81
- Petrelintide 5.0 mgn = 83
- Petrelintide 7.0 mgn = 79
- Petrelintide 9.0 mgn = 82
- Placebon = 81reference
- Primary endpoint
- Percentage change in bodyweight from baseline
- Follow-up
- 28 weeks
Methodological detailsmulticentre, double-blind, placebo-controlled, phase 2, Analyses included all randomly assigned participants who received ≥1 dose; missing data assumed missing at random
- Multicentre
- Double-blind
- Placebo-controlled
- Phase 2
- Analyses included all randomly assigned participants who received ≥1 dose; missing data assumed missing at random
Primary result
As reported in the abstract
Mean percentage change in bodyweight
Petrelintide 1.0 mg
−7.9
mean · CI −9.0–-6.7 · %
Petrelintide 2.5 mg
−7.9
mean · CI −9.0–-6.7 · %
Petrelintide 5.0 mg
−9.8
mean · CI −10.9–-8.6 · %
Petrelintide 7.0 mg
−9.3
mean · CI −10.5–-8.2 · %
Petrelintide 9.0 mg
−9.4
mean · CI −10.5–-8.3 · %
Placebo
−1.7
mean · CI −2.8–-0.5 · %
Each group vs placeboEstimated treatment difference, % (95% CI)
Petrelintide 1.0 mg
−6.2(−7.9 to −4.5)
Petrelintide 2.5 mg
−6.2(−7.8 to −4.5)
Petrelintide 5.0 mg
−8.1(−9.7 to −6.5)
Petrelintide 7.0 mg
−7.7(−9.3 to −6.0)
Petrelintide 9.0 mg
−7.7(−9.4 to −6.1)
Further findings
Bodyweight change to week 42
- Bodyweight continued to decline to week 42, with reductions of up to −10.7% with petrelintide
Safety
Adverse events
- Nausea, petrelintide (most common AE)
- 79 [20%] of 404
- Nausea, placebo
- five [6%]
- Vomiting, petrelintide
- 12 [3%]
- Vomiting, placebo
- five [6%]
- Diarrhoea, petrelintide
- 30 [7%]
- Diarrhoea, placebo
- six [7%]
- Constipation, petrelintide
- 28 [7%]
- Constipation, placebo
- three [4%]
- Deaths
- 0
Original publication
Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. Published 29 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →